Skip to main content
Research

Publications: Prof Peter Schmid

Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS et al. ( 2021 ) . A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer . Breast Cancer Research vol. 23 , ( 1 )
Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J et al. ( 2021 ) . Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study . npj Breast Cancer vol. 7 , ( 1 )
Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R et al. ( 2021 ) . Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer . European Journal of Cancer vol. 148 , 134 - 145 .
Pérez-García JM, Llombart-Cussac A, G. Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L et al. ( 2021 ) . Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial . European Journal of Cancer vol. 148 , 382 - 394 .
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD et al. ( 2021 ) . Sacituzumab govitecan in metastatic triple-negative breast cancer . New England Journal of Medicine vol. 384 , ( 16 ) 1529 - 1541 .
Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N et al. ( 2021 ) . First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors . EClinicalMedicine vol. 34 ,
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K et al. ( 2021 ) . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 22 , ( 4 ) 499 - 511 .
Hall PE, Schmid P ( 2021 ) . Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials . Expert Opinion on Emerging Drugs
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, Hu P et al. ( 2020 ) . Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: A meta-analysis . Cancer Research vol. 80 , ( 24 ) 5427 - 5434 .
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O et al. ( 2020 ) . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial . The Lancet vol. 396 , ( 10265 ) 1817 - 1828 .
Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, Ní Dhochartaigh S, Tran I, Leslie I et al. ( 2020 ) . Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage . Health and Quality of Life Outcomes vol. 18 , ( 1 )
Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ ( 2020 ) . The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer . Breast Cancer Research and Treatment vol. 183 , ( 3 ) 629 - 638 .
Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P et al. ( 2020 ) . A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer . Clinical Cancer Research vol. 26 , ( 16 )
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggsl A, Karantza V et al. ( 2020 ) . Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer . JNCCN Journal of the National Comprehensive Cancer Network vol. 18 , ( 8 ) 1096 - 1104 .
Schmid P, Dent R, O'Shaughnessy J ( 2020 ) . Pembrolizumab for Early Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 382 , ( 26 )
Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al. ( 2020 ) . Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer . Annals of Oncology vol. 31 , ( 5 ) 582 - 589 .
Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T et al. ( 2020 ) . Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study . Annals of Oncology vol. 31 , ( 5 ) 569 - 581 .
Schmid P, Cortes L, Pusztai L ( 2020 ) . Pembrolizumab plus Neoadjuvant Chemotherapy Improves Pathologic Complete Response Rates in Triple-Negative Breast Cancer . Journal of Clinical Outcomes Management vol. 27 , ( 2 ) 53 - 55 .
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al. ( 2020 ) . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer . Future Oncology vol. 16 , ( 12 ) 705 - 712 .
Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S et al. ( 2020 ) . Enhancing global access to cancer medicines . CA Cancer Journal for Clinicians vol. 70 , ( 2 ) 105 - 124 .
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al. ( 2020 ) . Pembrolizumab for early triple-negative breast cancer . New England Journal of Medicine vol. 382 , ( 9 ) 810 - 821 .
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al. ( 2020 ) . Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial . Journal of Clinical Oncology vol. 38 , ( 5 ) 423 - 433 .
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V et al. ( 2020 ) . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 44 - 59 .
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2019 ) . Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial . JAMA Oncology vol. 5 , ( 11 ) 1556 - 1563 .
Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM et al. ( 2019 ) . IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer . Future Oncology vol. 15 , ( 17 ) 1951 - 1961 .
Rosenthal R, Cadieux EL, Salgado R, Al-Bakir M, Moore DA, Hiley CT, Lund T, Tani¿ M et al. ( 2019 ) . Neoantigen-directed immune escape in lung cancer evolution . Nature vol. 567 , ( 7749 ) 479 - 485 .
Schmid P, Chui SY, Emens LA ( 2019 ) . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 380 , ( 10 ) 987 - 988 .
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al. ( 2019 ) . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 397 - 404 .
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2019 ) . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 405 - 411 .
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R et al. ( 2019 ) . Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study . JAMA Oncology vol. 5 , ( 1 ) 74 - 82 .
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al. ( 2018 ) . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer . New England Journal of Medicine vol. 379 , ( 22 ) 2108 - 2121 .
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ et al. ( 2018 ) . FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC . Journal of Thoracic Oncology vol. 13 , ( 11 ) 1733 - 1742 .
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I et al. ( 2018 ) . Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) . Proceedings of the National Academy of Sciences of the United States of America vol. 115 , ( 43 ) E10119 - E10126 .
Schmid P ( 2018 ) . ESMO 2018 presidential symposium - IMpassion130: Atezolizumab+nab-paclitaxel in triple-negative breast cancer . ESMO Open vol. 3 , ( 6 )
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al. ( 2018 ) . IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 , viii707 - viii708 .
Chau I, Haag GM, Rahma OE, Macarulla TM, McCune SL, Yardley DA, Solomon BJ, Johnson M et al. ( 2018 ) . MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 , viii439 - viii440 .
Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al. ( 2018 ) . Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers . BJS Open vol. 2 , ( 4 ) 162 - 174 .
Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. ( 2018 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . Journal of Clinical Oncology . vol. 36 , tps602 - tps602 .
Schmid PJ, Garciá-Gutierrez A, Jiménez J ( 2018 ) . Description and detection of burst events in turbulent flows . Journal of Physics: Conference Series . vol. 1001 ,
Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH et al. ( 2018 ) . Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies . Cancer Cell vol. 33 , ( 4 ) 649 - 663.e4 .
Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al. ( 2018 ) . Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort . HIV Medicine vol. 19 , ( 4 ) 252 - 260 .
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE et al. ( 2018 ) . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study . The Lancet Oncology vol. 19 , ( 4 ) 521 - 536 .
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al. ( 2018 ) . PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer . Cell Reports vol. 22 , ( 9 ) 2469 - 2481 .
Nathan MR, Schmid P ( 2018 ) . The emerging world of breast cancer immunotherapy . Breast vol. 37 , 200 - 206 .
Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al. ( 2018 ) . The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people . HIV Medicine vol. 19 , ( 2 ) 90 - 101 .
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P et al. ( 2018 ) . Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer . Journal of Clinical Oncology vol. 36 , ( 9 ) 884 - 890 .
O'Leary K, Shia A, Schmid P ( 2017 ) . Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer . Curr Cancer Drug Targets vol. 18 , ( 1 ) 89 - 96 .
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M ( 2017 ) . The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies . Cancer Treatment Reviews vol. 61 , 53 - 60 .
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S et al. ( 2017 ) . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution . Cell vol. 171 , ( 6 ) 1259 - 1271.e11 .
Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P ( 2017 ) . Nivolumab in HIV-related non-small-cell lung cancer . Annals of Oncology vol. 28 , ( 11 )
De Laurentiis M, Montemurro F, Bachelot T, Martin M, Barrios C, Kaufman B, Schmid P, Alba E et al. ( 2017 ) . The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer: the EarLEE adjuvant clinical trials program . Annals of oncology : official journal of the European Society for Medical Oncology vol. 28 ,
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . ANNALS OF ONCOLOGY . Conference: ESMO vol. 28 ,
Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. ( 2017 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 134 - 134 .
Martin Jimenez M, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. ( 2017 ) . EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC) . ANNALS OF ONCOLOGY . vol. 28 ,
Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2017 ) . Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 . ANNALS OF ONCOLOGY . vol. 28 ,
Beddowes E, Spicer J, Chan PY, Khadeir R, Garcia Corbacho J, Repana D, Steele JP, Schmid P et al. ( 2017 ) . Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers . Journal of Clinical Oncology vol. 35 , ( 16 ) 1778 - 1785 .
Schmid P, Forster MD, Summers YJ, Good J, Sarker S-J, Lim L, Mousa K, Middleton GW ( 2017 ) . A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results . JOURNAL OF CLINICAL ONCOLOGY . Conference: ESMO vol. 35 ,
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al. ( 2017 ) . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort . Clinical Infectious Diseases vol. 64 , ( 10 ) 1413 - 1421 .
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S et al. ( 2017 ) . Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR) . Journal of Clinical Oncology vol. 35 , ( 14 ) 1506 - 1514 .
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA ( 2017 ) . Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial . TRIALS . Conference: ICTMC/SCT 2017 vol. 18 ,
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA et al. ( 2017 ) . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution . Nature vol. 545 , ( 7655 ) 446 - 451 .
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R et al. ( 2017 ) . Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors . Immunity vol. 46 , ( 4 ) 577 - 586 .
Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P ( 2017 ) . Abstract P3-03-12: CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy .
López-Miranda E, Gávila J, Pernas S, Saura C, Oliveira M, Serra V, Schmid P, Lord S et al. ( 2017 ) . Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007) .
Schmid P, Pinder SE, Purushotham A, Thompson AM ( 2017 ) . Reply to R.F. Sweis et al . Journal of Clinical Oncology vol. 35 , ( 2 ) 261 - 262 .
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial . JAMA oncology vol. 3 , ( 1 ) 58 - 66 .
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial . JAMA Oncology vol. 3 , ( 1 ) E1 - E9 .
Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P ( 2016 ) . Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study . Clinical Breast Cancer vol. 16 , ( 6 ) 514 - 519 .
Mok T, Schmid P, Jr DCG, Syrigos K, Martin C, Yamamoto N, Aren O, Arrieta O et al. ( 2016 ) . Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 27 ,
Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. ( 2016 ) . IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC . ANNALS OF ONCOLOGY . vol. 27 ,
Ma BBY, Rudin CM, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor VM et al. ( 2016 ) . Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC . ANNALS OF ONCOLOGY . vol. 27 ,
Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG et al. ( 2016 ) . METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC) . Annals of Oncology . vol. 27 ,
Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK et al. ( 2016 ) . Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant . Nature Communications vol. 7 , ( 1 )
Lenihan C, Cavicchioli F, O¿Leary K, Shia A, Schmid P ( 2016 ) . Abstract 2110: The role of VAV-interacting Kruppel-like factor (VIK) in resistance to palbociclib in estrogen receptor-positive breast cancer . 2110 - 2110 .
Bouchekioua-Bouzaghou K, Lenihan C, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P ( 2016 ) . Abstract 2819: Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib . 2819 - 2819 .
Komulainen E, Shia A, Bansal J, Cavicchioli F, O¿Leary K, Foster J, Schmid P ( 2016 ) . Abstract 3759: Inhibition of heat shock protein 27 (Hsp27) expression by apatorsen as a therapeutic strategy in breast cancer . 3759 - 3759 .
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2016 ) . Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer . Journal of Clinical Oncology vol. 34 , ( 17 ) 1987 - 1994 .
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B et al. ( 2016 ) . Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial . The Lancet Oncology vol. 17 , ( 6 ) 811 - 821 .
Schmid P, Wheatley DA, Thompson AM, Roy P, Bundred NJ, Purushotham AD, McIntosh S, Kummel S et al. ( 2016 ) . ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 34 ,
Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K et al. ( 2016 ) . 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC . Journal of Thoracic Oncology vol. 11 , ( 4 ) S140 - S141 .
Cortes J, Martinez Janesz N, Sablin MP, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart MP et al. ( 2016 ) . Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part . EUROPEAN JOURNAL OF CANCER . vol. 57 , S112 - S112 .
Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L et al. ( 2016 ) . Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? . Breast vol. 26 , 149 - 150 .
Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E ( 2016 ) . Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) .
Schmid P, Ferreira M, Dubey S, Zaiss M, Harper-Wynne C, Makris A, Brown V, Kristeleit H et al. ( 2016 ) . Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer .
Schmid P, Wheatley D, Baird R, Chan S, Abraham J, Tutt A, Kristeleit H, Patel G et al. ( 2016 ) . Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603) .
Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P ( 2016 ) . Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer .
Hampsch R, Shee K, Miller T ( 2016 ) . Abstract P5-03-01: Therapeutic targeting of Rac GTPases in ER+ and HER2+ breast cancer .
Schmid P, Pinder S, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R et al. ( 2016 ) . Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study) .
Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) .
Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) . CANCER RESEARCH . vol. 76 ,
Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. ( 2015 ) . Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 26 , 147 - 147 .
Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel EE, Chaft J et al. ( 2015 ) . 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes . European Journal of Cancer . vol. 51 ,
Schmid P, Muthukumar D, Blackhall F, Lester J, Khan S, Illsley MC, Adams J, Baijal S et al. ( 2015 ) . Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar (TM) Trial . JOURNAL OF THORACIC ONCOLOGY vol. 10 , ( 9 ) S664 - S664 .
O Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer
Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR et al. ( 2015 ) . Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer . Annals of Oncology vol. 26 , ( 9 ) 1904 - 1910 .
Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. ( 2015 ) . Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. ( 2015 ) . Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. ( 2015 ) . Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer . Journal of Clinical Oncology . vol. 33 , tps2612 - tps2612 .
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC) . ANNALS OF ONCOLOGY . vol. 26 ,
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) . Annals of Oncology vol. 26 ,
Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S et al. ( 2015 ) . Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results .
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2015 ) . Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study) .
O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer vol. 113 , ( 6 ) 970 - 978 .
Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D ( 2015 ) . Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression . Journal of Neuroimmunology vol. 287 , 88 - 92 .
Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R et al. ( 2014 ) . Effects of hiking at moderate and low altitude on cardiovascular parameters in male patients with metabolic syndrome: Austrian Moderate Altitude Study . Wilderness & environmental medicine vol. 25 , ( 3 ) 329 - 334 .
Meisenberg C, Ward SE, Schmid P, El-Khamisy SF ( 2014 ) . TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan . J Cancer Sci Ther vol. 6 , ( 7 ) 258 - 267 .
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P ( 2014 ) . A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer . BMC Medicine vol. 12 , ( 1 )
Dizdarevic S, McCready R, Turner JFC, Bagley MC, Blower P, Schmid P, Flux G, Hall A et al. ( 2014 ) . Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41 , ( 6 ) 1255 - 1256 .
Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME et al. ( 2014 ) . A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer . Journal of Clinical Oncology . vol. 32 , tps1144 - tps1144 .
Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löbner C, Jung S, Böhm G et al. ( 2014 ) . Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets . PLoS ONE vol. 9 , ( 3 )
Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N et al. ( 2014 ) . A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer . ANNALS OF ONCOLOGY vol. 25 , ( 2 ) 505 - 511 .
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2014 ) . Practice guidelines for exercise testing . Atemwegs- und Lungenkrankheiten vol. 40 , ( 6 ) 223 - 244 .
Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P ( 2013 ) . Abstract P2-09-05: The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes .
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al. ( 2013 ) . Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer . Breast Cancer Research vol. 15 , ( 5 )
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson AM, Lackner M, Jones LJ et al. ( 2013 ) . Sensitivity to glutamine deprivation is dependent on the interplay between epigenetic regulation of Glutamine synthetase (Glul) and induction of autophagy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S141 - S141 .
Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A et al. ( 2013 ) . A phase i dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer . Breast Cancer Research and Treatment vol. 140 , ( 1 ) 73 - 82 .
Cope S, Ouwens MJNM, Jansen JP, Schmid P ( 2013 ) . Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: A network meta-analysis with parametric survival models . Value in Health vol. 16 , ( 2 ) 403 - 417 .
Eder B, Hofmann P, Hödl R, Wonisch M, Schmid P, Pokan R ( 2013 ) . Cardiac rehabilitation effective in elderly patients? . Journal fur Kardiologie vol. 20 , ( 9-10 ) 262 - 268 .
Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider . SCIENCE vol. 338 , ( 6114 ) 1576 - 1582 .
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson A, Lackner M, Lo NC et al. ( 2012 ) . Abstract P4-06-10: Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy .
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E et al. ( 2012 ) . Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) . Lung Cancer vol. 78 , ( 3 ) 239 - 244 .
Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D et al. ( 2012 ) . The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma . British Journal of Cancer vol. 107 , ( 8 ) 1423 - 1432 .
Aad G, Abajyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC . Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 716 , ( 1 ) 1 - 29 .
Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. ( 2012 ) . EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER . ANNALS OF ONCOLOGY . vol. 23 , 532 - 533 .
O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. ( 2012 ) . IDENTIFICATION OF ENDOGLIN (CD105) AS AN EPIGENETICALLY REGULATED CANDIDATE TUMOUR SUPPRESSOR GENE IN LUNG CANCER . ANNALS OF ONCOLOGY . vol. 23 , 73 - 74 .
Wonisch M, Marko C, Niebauer J, Pokan R, Schmid P, Wiesinger E ( 2012 ) . Resistance training for patients with cardiovascular diseases . Wiener Klinische Wochenschrift vol. 124 , ( 9-10 ) 326 - 333 .
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Niebauer J, Sinzinger H, Schmid P ( 2012 ) . Discontinuation of combined resistance-endurance training increases cardiovascular risk factors . International Journal of Cardiology vol. 156 , ( 2 ) 229 - 231 .
Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wur¿schmidt F, Petry KU, Kimmig R et al. ( 2011 ) . Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGO-AGO intergroup study . Journal of Clinical Oncology vol. 29 , ( 28 ) 3791 - 3797 .
Berent R, Von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P ( 2011 ) . Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: A randomized trial . Archives of Physical Medicine and Rehabilitation vol. 92 , ( 10 ) 1527 - 1533 .
Berent R, Auer J, Franklin B, Schmid P, Von Duvillard SP ( 2011 ) . Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period . American Journal of Cardiology vol. 108 , ( 5 ) 644 - 650 .
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al. ( 2011 ) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials . The Lancet vol. 378 , ( 9793 ) 771 - 784 .
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M et al. ( 2011 ) . High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials . Journal of Clinical Oncology vol. 29 , ( 24 ) 3224 - 3231 .
Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran FA et al. ( 2011 ) . Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes . Anticancer Research vol. 31 , ( 8 ) 2617 - 2622 .
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU et al. ( 2011 ) . Prognostic significance of angiogenic factors in uterine cervical cancer . Anticancer Research vol. 31 , ( 8 ) 2589 - 2595 .
Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al. ( 2011 ) . Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer . Cancer Res vol. 71 , ( 9 ) 3317 - 3327 .
White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P ( 2011 ) . Characterisation of transient benign hCG elevations in women following chemotherapy for GTT . Journal of Obstetrics and Gynaecology vol. 31 , ( 2 ) 169 - 172 .
SCHMID-ARAYA J, Figueroa Hernandez D, Schmid PE, Drouot C ( 2011 ) . Algivory in food webs of three temperate Andean rivers . Austral Ecology
Berent R, Auer J, Schmid P, Krennmair G, Crouse SF, Green JS, Sinzinger H, Von Duvillard SP ( 2011 ) . Periodontal and coronary heart disease in patients undergoing coronary angiography . Metabolism: Clinical and Experimental vol. 60 , ( 1 ) 127 - 133 .
Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, Lang IM, Marko C et al. ( 2011 ) . Practical implementation of guidelines for lipid lowering . Journal fur Kardiologie vol. 18 , ( 3-4 ) 96 - 99 .
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons . EUR PHYS J C vol. 70 , ( 3 ) 755 - 785 .
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Readiness of the ATLAS liquid argon calorimeter for LHC collisions . EUR PHYS J C vol. 70 , ( 3 ) 723 - 753 .
Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D ( 2010 ) . Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer . Integrative Cancer Therapies vol. 9 , ( 3 ) 270 - 275 .
Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H ( 2010 ) . Prickly pear changes <sup>111</sup>indium?LDL and <sup>111</sup>indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia . Journal of the Professional Association for Cactus Development vol. 12 , 67 - 79 .
Blackhall FH, Obrien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N ( 2010 ) . A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer . Journal of Thoracic Oncology vol. 5 , ( 8 ) 1285 - 1288 .
Berent R, Auer J, Von Duvillard SP, Sinzinger H, Schmid P ( 2010 ) . Complications during exercise testing . Herz vol. 35 , ( 4 ) 267 - 272 .
Schmid PE, Schmid-Araya JM ( 2010 ) . Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream . FUND APPL LIMNOL vol. 176 , ( 4 ) 365 - 375 .
McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ ( 2010 ) . The management and outcome of women with post-hydatidiform mole low-risk gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l<sup>-1</sup> . British Journal of Cancer vol. 102 , ( 5 ) 810 - 814 .
Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G et al. ( 2010 ) . Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial . Annals of Oncology vol. 21 , ( 7 ) 1430 - 1435 .
Berent R, Auer J, Von Duvillard S, Sinzinger H, Steinbrenner D, Schmid P ( 2010 ) . Acute myocardial infarction with ST segment elevation in inferior and anterior leads: Right ventricular infarction . BMJ Case Reports
Berent R, von Duvillard SP, Auer J, Sinzinger H, Schmid P ( 2010 ) . Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors . European Journal of Preventive Cardiology vol. 17 , ( 3 ) 296 - 302 .
Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al. ( 2010 ) . Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast . Journal of the National Cancer Institute - Monographs vol. 41 , 162 - 177 .
Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H et al. ( 2009 ) . Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors . Annals of Oncology vol. 21 , ( 3 ) 633 - 639 .
Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al. ( 2009 ) . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer . Int J Cancer vol. 125 , ( 6 ) 1454 - 1463 .
Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, Lindsay I, Wells M et al. ( 2009 ) . Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study . The Lancet vol. 374 , ( 9683 ) 48 - 55 .
Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T et al. ( 2009 ) . Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial . Cancer Chemotherapy and Pharmacology vol. 64 , ( 2 ) 401 - 406 .
Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J et al. ( 2009 ) . Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer . Anticancer Research vol. 29 , ( 2 ) 641 - 645 .
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Sinzinger H, Schmid P ( 2009 ) . Short-term residential cardiac rehabilitation reduces B-type natriuretic peptide . European Journal of Cardiovascular Prevention and Rehabilitation vol. 16 , ( 5 ) 603 - 608 .
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ et al. ( 2009 ) . Third consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 20 , ( 11 ) 1771 - 1785 .
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2008 ) . Practice guidelines for exercise testing . Journal fur Kardiologie vol. 15 , ( SUPPL. A ) 3 - 17 .
Harvey RA, Pursglove HD, Schmid P, Savage PM, Mitchell HDC, Seckl MJ ( 2008 ) . Human chorionic gonadotropin free β-subunit measurement as a marker of placental site trophoblastic tumors . Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53 , ( 8 ) 643 - 648 .
Lim AKP, Patel D, Patel N, Hawtin K, Dayal L, Schmid P, Savage P, Seckl MJ ( 2008 ) . Pelvic imaging in gestational trophoblastic neoplasia . Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53 , ( 8 ) 575 - 578 .
Aad G, Abat E, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi BA, Abolins M et al. ( 2008 ) . The ATLAS Experiment at the CERN Large Hadron Collider . J INSTRUM vol. 3 , Article S08003 ,
Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J et al. ( 2008 ) . A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines . Annals of Oncology vol. 19 , ( 5 ) 871 - 876 .
Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ ( 2008 ) . Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy . Cancer Chemotherapy and Pharmacology vol. 61 , ( 2 ) 347 - 348 .
Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ ( 2008 ) . Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/ etoposide (TP/TE) . Annals of Oncology vol. 19 , ( 9 ) 1578 - 1583 .
Schmid P ( 2007 ) . Bisphosphonate for the treatment of tumor induced in bone changes . Onkologe vol. 13 , ( 7 ) 609 - 618 .
Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS et al. ( 2007 ) . Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93 . Annals of Oncology vol. 18 , ( 7 ) 1177 - 1184 .
Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L et al. ( 2007 ) . Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study . Journal of Clinical Oncology vol. 25 , ( 18 ) 2509 - 2515 .
Schmid P ( 2007 ) . High-dose chemotherapy for breast cancer . Onkologe vol. 13 , ( 5 ) 409 - 424 .
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . British Journal of Cancer vol. 96 , ( 5 ) 732 - 737 .
Kümmel S, Rezai M, Kimmig R, Schmid P ( 2007 ) . Dose-dense chemotherapy for primary breast cancer . Current Opinion in Obstetrics and Gynecology vol. 19 , ( 1 ) 75 - 81 .
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J et al. ( 2007 ) . Second consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 18 , ( 2 ) 215 - 225 .
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R et al. ( 2007 ) . Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes . International Journal of Biological Markers vol. 22 , ( 3 ) 186 - 193 .
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416) . British Journal of Cancer vol. 95 , ( 12 )
Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K et al. ( 2006 ) . Biomarkers of depression in cancer patients . Cancer vol. 107 , ( 11 ) 2723 - 2729 .
Possinger K, Schmid P ( 2006 ) . Chemotherapy for metastatic breast cancer . Zentralblatt fur Gynakologie vol. 128 , ( 6 ) 318 - 326 .
Schmid P ( 2006 ) . Mechanism of action and application possibilities: Adjuvant hormonal therapy of breast carcinoma . Best Practice Onkologie vol. 1 , ( 1 ) 42 - 57 .
Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . British Journal of Cancer vol. 95 , ( 9 ) 1145 - 1147 .
Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Frank J et al. ( 2006 ) . Value of whole body <sup>18</sup>FDG-PET to identify the active site of gestational trophoblastic neoplasia . Journal of Reproductive Medicine for the Obstetrician and Gynecologist . vol. 51 , 879 - 887 .
Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES et al. ( 2006 ) . Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment . Journal of Clinical Oncology vol. 24 , ( 30 ) 4862 - 4866 .
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M et al. ( 2006 ) . Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients . British Journal of Sports Medicine vol. 40 , ( 9 ) 773 - 778 .
Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . J Clin Oncol vol. 24 , ( 18_suppl )
Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G et al. ( 2006 ) . Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes . Anticancer Research . vol. 26 , 1719 - 1726 .
Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A ( 2006 ) . Chemotherapy treatment options for elderly women with breast cancer . Anticancer Research . vol. 26 , 1673 - 1676 .
Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M et al. ( 2005 ) . Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial . Journal of Clinical Oncology vol. 23 , ( 3 ) 432 - 440 .
Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K et al. ( 2005 ) . Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study . Journal of Cancer Research and Clinical Oncology vol. 131 , ( 9 ) 568 - 574 .
Schmid P, Flath B, Akrivakis K, Heilmann V, Mergenthaler HG, Sezer O, Kreienberg R, Possinger K ( 2005 ) . Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study . Investigational New Drugs vol. 23 , ( 4 ) 349 - 356 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Gynakologische Praxis vol. 29 , ( 2 ) 351 - 358 .
Schmid P, Possinger K ( 2005 ) . Gemcitabine (Gemzar) . Internistische Praxis vol. 45 , ( 2 ) 415 - 422 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Padiatrische Praxis vol. 66 , ( 3 ) 521 - 528 .
Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K et al. ( 2005 ) . Proteasome: An emerging target for cancer therapy . Anti-Cancer Drugs vol. 16 , ( 5 ) 475 - 481 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Chirurgische Praxis vol. 64 , ( 2 ) 351 - 358 .
Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K ( 2005 ) . Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study . Investigational New Drugs vol. 23 , ( 2 ) 139 - 146 .
Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S et al. ( 2005 ) . Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial . Annals of Oncology vol. 16 , ( 10 ) 1624 - 1631 .
Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU et al. ( 2005 ) . Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: Results of a phase I trial . Anti-Cancer Drugs vol. 16 , ( 1 ) 21 - 29 .
Pokan R, Von Duvillard SP, Ludwig J, Rohrer A, Hofmann P, Wonisch M, Smekal G, Schmid P et al. ( 2004 ) . Effect of high-volume and -intensity endurance training in heart transplant recipients . Medicine and Science in Sports and Exercise vol. 36 , ( 12 ) 2011 - 2016 .
Untch M, Kahlert S, Kosse V, Bondar G, Kienle E, Maubach L, Hillger H, Schmid P et al. ( 2004 ) . Leuprorelinacetate as a 3 month depot has the same efficacy as CMF in the adjuvant therapy of pre-perimenopausal, node positive breast cancer patients with positive receptor status - The TABLE study . Geburtshilfe und Frauenheilkunde vol. 64 , ( 12 ) 1316 - 1323 .
Dieing A, Schulz CO, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K ( 2004 ) . Orbital metastases in breast cancer: Report of two cases and review of the literature . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 12 ) 745 - 748 .
Schmid P, Helmreich G, Gradauer L, Stowasser G, Bronnenmayer J, Pokan R ( 2004 ) . Are there non responders to exercise therapy after myocardial infarction? . Journal fur Kardiologie vol. 11 , ( 11 ) 453 - 457 .
Pokan R, Hofmann P, Wonisch M, Smekal G, Bachl N, Mayr K, Benzer W, Schmid P ( 2004 ) . Performance diagnostic and target training heart rate in cardiac rehabilitation . Journal fur Kardiologie vol. 11 , ( 11 ) 446 - 452 .
Höfer S, Benzer W, Brandt D, Laimer H, Schmid P, Bernardo A, Oldridge NB ( 2004 ) . MacNew Heart Disease Questionnaire after myocardial infarction: The German version . Zeitschrift fur Klinische Psychologie und Psychotherapie vol. 33 , ( 4 ) 270 - 280 .
Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T et al. ( 2004 ) . Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: Final results of a multicenter phase II study . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 11 ) 657 - 663 .
Schmid P, Helmreich G, Gradauer L, Schmid F ( 2004 ) . Percutaneous transradial artery approach for coronary diagnostics and PCI . Journal fur Kardiologie vol. 11 , ( 9 ) 359 - 362 .
Pokan R, Wonisch M, Schmid P ( 2004 ) . Changes in the athlete's heart in the ECG . Internistische Praxis vol. 44 , ( 1 ) 79 - 88 .
Schmid P, Schmid F, Smekal G, Pokan R ( 2003 ) . Physical Activity and Primary Prevention . Journal fur Kardiologie vol. 10 , ( 12 ) 548 - 553 .
Beslija S, Bonneterre J, Burstein HJ, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W et al. ( 2003 ) . Consensus on medical treatment of metastatic breast cancer . Breast Cancer Research and Treatment . vol. 81 ,
Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K ( 2003 ) . Upregulation of HER-2/neu by ovarian ablation: Results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients . Breast Cancer Research and Treatment vol. 80 , ( 3 ) 245 - 255 .
Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O ( 2003 ) . Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer . British Journal of Cancer vol. 88 , ( 9 ) 1406 - 1410 .
Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hörtnagl H, Gunga HC, Klingler A, Fries D et al. ( 2003 ) . Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome . European Journal of Applied Physiology vol. 88 , ( 6 ) 506 - 514 .
Schmid P, Possinger K ( 2003 ) . Bisphosphonates in metastatic breast cancer . Breast Cancer Research and Treatment . vol. 81 ,
Schmid P, Possinger K ( 2003 ) . Which treatment when? . Breast Cancer Research and Treatment . vol. 81 ,
Schmid P, Possinger K ( 2002 ) . Interactions of antioestrogens and aromatase inhibitors . FORUM - Trends in Experimental and Clinical Medicine vol. 12 , ( 1 ) 45 - 59 .
Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K ( 2002 ) . Prediction of response to hormonal treatment in metastatic breast cancer . Oncology vol. 63 , ( 4 ) 309 - 316 .
Schmid P, Possinger K ( 2002 ) . High-dose chemotherapy in breast cancer . Medizinische Klinik vol. 97 , ( 11 ) 677 - 686 .
Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D et al. ( 2002 ) . The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas . Anti-Cancer Drugs vol. 13 , ( 9 ) 907 - 913 .
Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E et al. ( 2002 ) . Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate) . Anticancer Research vol. 22 , ( 4 ) 2325 - 2332 .
Schmid P, Possinger K ( 2002 ) . High-dose chemotherapy in high-risk primary breast cancer . Onkologie vol. 25 , ( 2 ) 112 - 120 .
Schmid P, Possinger K ( 2002 ) . Systemic therapy in breast cancer - Adjuvant and neo-adjuvant treatment: Update situation and update studies . Viszeralchirurgie vol. 37 , ( 2 ) 137 - 149 .
Schmid P, Possinger K ( 2002 ) . Adjuvant and neoadjuvant systemic therapy of breast cancer . Internist vol. 43 , ( 3 ) 341 - 353 .
Pokan R, Hofmann P, Smekal G, Wonisch M, Bachl N, Schmid P ( 2002 ) . Performance testing for regulating training in exercise therapy of cardiovascular disease . Internistische Praxis vol. 42 , ( 4 ) 797 - 806 .
Schmid P, Sezer O, Possinger K ( 2001 ) . Bisphosphonates in oncology . Pharmazie in Unserer Zeit vol. 30 , ( 6 ) 519 - 528 .
Schmid P, Fritz J, Possinger K ( 2001 ) . Treatment options for metastatic breast cancer . Internistische Praxis vol. 41 , ( 2 ) 319 - 332 .
Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K ( 2001 ) . Achievement of complete remission in refractory Hodgkin's disease with prolonged infussion of gemcitabine . Investigational New Drugs vol. 19 , ( 1 ) 101 - 104 .
Sinzinger H, Hoppichler F, Kritz H, Laimer H, Schmid P, Silberbauer K, Toplak H ( 2001 ) . HDL-2000 - Ein konsensus . Wiener Klinische Wochenschrift vol. 113 , ( 5-6 ) 212 - 214 .
Grosse Y, Schmid P, Possinger K ( 2001 ) . Bisphosphonates in the treatment of breast cancer. Prevention and adjuvant therapy . Tagliche Praxis vol. 42 , ( 4 ) 727 - 734 .
Pokan R, Pelikan J, Retzer H, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Fruhwald FM et al. ( 2001 ) . Leistungsfähigkeit und herzfrequenz von patienten mit KHK im MAXLASS und deren zusammenhang mit dem herzfrequenzverhalten und der myokardialen funktion unter belastung im stufentest . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )
Schmid P, Possinger K ( 2001 ) . Liposomal anthracyclines for improved cardiac tolerability . Breast vol. 10 , ( SUPPL. 2 ) 22 - 27 .
Schmid P ( 2001 ) . Stellenwert der Bewegungstherapie in der Primär- und Sekundärprävention der KHK . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )
Lueftner DI, Schmid P, Kienle E, Possinger K ( 2001 ) . Upregulation of Her-2/neu under chemical castration: Serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer . Breast Cancer Research and Treatment vol. 69 , ( 3 )
Sezer O, Eucker J, Jakob C, Schmid P, Possinger K ( 2000 ) . Prolonged infusion of gemcitabine in refractory hodgkin's disease . Blood vol. 96 , ( 11 PART II )
Possinger K, Schmid P ( 2000 ) . Therapeutic possibilities in breast carcinoma . Onkologe . vol. 6 ,
Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K ( 2000 ) . Detection of HMGI-C in the peripheral blood of breast cancer patients . European Journal of Cancer vol. 36 , ( 15 ) 1944 - 1948 .
Schmid PE, Tokeshi M, Schmid-Araya JM ( 2000 ) . Relation between population density and body size in stream communities . Science vol. 289 , ( 5484 ) 1557 - 1560 .
Schmid P, Possinger K ( 2000 ) . Advanced breast cancer. Palliative measures are becoming ever more tolerable . MMW-Fortschritte der Medizin vol. 142 , ( 35 ) 22 - 24 .
Possinger K, Schmid P ( 2000 ) . New drugs for the treatment of breast cancer . Onkologe vol. 6 , ( 5 ) 392 - 409 .
Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E ( 2000 ) . [Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance] . Berl Munch Tierarztl Wochenschr vol. 113 , ( 7-8 ) 299 - 305 .
Sinzinger H, Chehne F, Schmid P, Kritz H ( 2000 ) . Plasma homocysteine is not altered during simvastatin-therapy . Wiener Klinische Wochenschrift vol. 112 , ( 12 ) 540 - 543 .
Pokan R, Von Duvillard SP, Hofmann P, Smekal G, Fruhwald FM, Gasser R, Tschan H, Baron R et al. ( 2000 ) . Change in left atrial and ventricular dimensions during and immediately after exercise . Medicine and Science in Sports and Exercise vol. 32 , ( 10 ) 1713 - 1718 .
Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Stuschke M, Schweigert M, Siebert G et al. ( 2000 ) . Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy . Journal of Cancer Research and Clinical Oncology vol. 126 , ( 6 ) 352 - 356 .
Sezer O, Eucker J, Schmid P, Possinger K ( 2000 ) . New therapeutic approaches in primary systemic AL amyloidosis . Annals of Hematology vol. 79 , ( 1 ) 1 - 6 .
Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K ( 1999 ) . Eosinophila during fludarabine treatment of chronic lymphocytic leukemia . Annals of Hematology vol. 78 , ( 10 ) 475 - 477 .
Sinzinger H, Schmid P, O'Grady J ( 1999 ) . Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [3] . Atherosclerosis vol. 143 , ( 2 ) 459 - 460 .
Helmreich G, Gradauer L, Schmid P ( 1999 ) . Duration and complications in diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 545 - 549 .
Schmid P, Helmreich G, Gradauer L ( 1999 ) . Methods for diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 538 - 542 .
Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K ( 1999 ) . Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer . Anti-Cancer Drugs vol. 10 , ( 7 ) 625 - 631 .
Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K ( 1999 ) . Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study . Anti-Cancer Drugs vol. 10 , ( 6 ) 525 - 531 .
Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H et al. ( 1999 ) . Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support . Bone Marrow Transplantation vol. 23 , ( 9 ) 967 - 969 .
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Hogler R, Tschan H, Baron R, Schmid P et al. ( 1999 ) . The heart rate turn point reliability and methodological aspects . Medicine and Science in Sports and Exercise vol. 31 , ( 6 ) 903 - 907 .
Sezer O, Schmid P, Mergenthaler HG, Beinert T, Possinger K ( 1999 ) . Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases . Onkologie vol. 22 , ( 5 ) 400 - 404 .
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Smekal G, Gasser R, Klein W, Eber B et al. ( 1998 ) . The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction . Medicine and Science in Sports and Exercise vol. 30 , ( 10 ) 1475 - 1480 .
Pokan R, Hofmann P, Von Duvillard SP, Schumacher M, Gasser R, Zweiker R, Fruhwald FM, Eber B et al. ( 1998 ) . Parasympathetic receptor blockade and the heart rate performance curve . Medicine and Science in Sports and Exercise vol. 30 , ( 2 ) 229 - 233 .
Hofmann P, Pokan R, Von Duvillard SP, Schmid P, Conconi F, Grazzi G, Casoni I, Borsetto C et al. ( 1997 ) . The Conconi test (multiple letters) [2] . International Journal of Sports Medicine vol. 18 , ( 5 ) 397 - 399 .
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Schumacher M, Fruhwald FM, Zweiker R, Eber B et al. ( 1997 ) . Left ventricular function in response to the transition from aerobic to anaerobic metabolism . Medicine and Science in Sports and Exercise vol. 29 , ( 8 ) 1040 - 1047 .
Hofmann P, Pokan R, Bachl N, Schmid P ( 1997 ) . A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31-4) . The Journal of sports medicine and physical fitness vol. 37 , ( 2 ) 151 - 155 .
O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H ( 1997 ) . Effect of isradipine on in-vivo platelet function . Thrombosis Research vol. 86 , ( 5 ) 363 - 371 .
Hofmann P, Pokan R, Von Duvillard SP, Seibert FJ, Zweiker R, Schmid P ( 1997 ) . Heart rate performance curve during incremental cycle ergometer exercise in healthy young male subjects . Medicine and Science in Sports and Exercise vol. 29 , ( 6 ) 762 - 768 .
Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H ( 1997 ) . Detection of early atherosclerotic lesions in the carotid artery: Experimental and preliminary human data . International Journal of Angiology vol. 6 , ( 1 ) 24 - 29 .
Kritz H, Schmid P, Karanikas G, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 1996 ) . Passive smoking increases platelet thromboxane . International Journal of Angiology vol. 5 , ( 3 ) 134 - 139 .
Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC ( 1996 ) . Testicular germ cell tumors in patients with human immunodeficiency virus infection . Cancer vol. 77 , ( 10 ) 2109 - 2116 .
Benzer W, Schmid P, Maehr G, Drexel H ( 1996 ) . Effects of intravenous magnesium chloride reverses left ventricular end-diastolic pressure in coronary artery disease . American Journal of Cardiology vol. 77 , ( 8 ) 638 - 640 .
Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 1996 ) . Passive smoking and platelet thromboxane . Thrombosis Research vol. 81 , ( 4 ) 451 - 460 .
Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R et al. ( 1996 ) . Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer . European Journal of Cancer Part A vol. 32 , ( 10 ) 1712 - 1718 .
Sinzinger H, Kritz H, Virgolini I, Schmid P, Rogatti W ( 1996 ) . Prostaglandin E<inf>1</inf> increases binding of<sup>123</sup>l-low-density lipoprotein to the human liver in vivo . European Journal of Clinical Pharmacology vol. 49 , ( 6 ) 515 - 520 .
Kritz H, Schmid P, Keiler A, O'Grady J, Sinzinger H ( 1995 ) . Isradipine increases vascular prostaglandin I<inf>2</inf>-formation while the thromboxane B<inf>2</inf>-synthesis is diminished . Thrombosis Research vol. 80 , ( 6 ) 483 - 489 .
Benzer W, Schmid P ( 1995 ) . Rehabilitation after myocardial infarct--a multidisciplinary responsibility . Wiener klinische Wochenschrift vol. 107 , ( 24 )
Kritz H, Schmid P, Sinzinger H ( 1995 ) . Passive Smoking and Cardiovascular Risk . Archives of Internal Medicine vol. 155 , ( 18 ) 1942 - 1948 .
Pokan R, Hofmann P, Lehmann M, Leitner H, Eber B, Gasser R, Schwaberger G, Schmid P et al. ( 1995 ) . Heart rate deflection related to lactate performance curve and plasma catecholamine response during incremental cycle ergometer exercise . European Journal of Applied Physiology and Occupational Physiology vol. 70 , ( 2 ) 175 - 179 .
Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA ( 1994 ) . Sleep disturbance and appetite loss after lovastatin . The Lancet vol. 343 , ( 8903 )
Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H ( 1994 ) . Influence of calcium antagonists on platelet function and vascular prostacyclin production . Blood Pressure, Supplement . vol. 3 , 75 - 80 .
Pirich C, Fitscha P, Schmid P, Sinzinger H ( 1994 ) . Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall . Blood Pressure, Supplement . vol. 3 , 70 - 74 .
Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H ( 1994 ) . Isradipine increases platelet - Low-density lipoprotein binding: Evidence from ex-vivo studies in humans . Blood Pressure, Supplement . vol. 3 , 65 - 69 .
Sinzinger H, Schmid P, Pirich C, Virgolini I, Pesau B, Granegger S, O'Grady J ( 1992 ) . Treatment of hypercholesterolaemia in children . The Lancet vol. 340 , ( 8818 ) 548 - 549 .
Pirich C, Schmid P, Pidlich J, Sinzinger H ( 1992 ) . Cholesterol lowering by Anticholest® - a high-fiber guar-pectin drink . Wiener Klinische Wochenschrift vol. 104 , ( 11 ) 314 - 316 .